IBI311 + Placebo

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Thyroid Eye Disease

Conditions

Thyroid Eye Disease

Trial Timeline

Sep 10, 2025 → Dec 31, 2027

NCT ID

NCT07113262

About IBI311 + Placebo

IBI311 + Placebo is a phase 3 stage product being developed by Innovent Biologics for Thyroid Eye Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07113262. Target conditions include Thyroid Eye Disease.

What happened to similar drugs?

20 of 20 similar drugs in Thyroid Eye Disease were approved

Approved (20) Terminated (4) Active (0)

✅LenvatinibEisaiApproved

✅Cinacalcet HClKyowa KirinApproved

✅Growth hormone + Growth hormone treatment and pubertyEli LillyApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07113262	Phase 3	Recruiting	Sep 10, 2025	Dec 31, 2027	Thyroid Eye Disease
NCT05795621	Phase 2/3	Completed	Feb 14, 2023	Dec 20, 2023	Thyroid Eye Disease

Competing Products

20 competing products in Thyroid Eye Disease

See all competitors

Product	Company	Stage	Hype Score
MBX 2109	MBX Biosciences	Phase 2	29
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection	MBX Biosciences	Phase 2	33
PCO371 + Placebo	Chugai Pharmaceutical	Phase 1	21
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib + Placebo + Lenvatinib	Eisai	Phase 3	40
Irofulven + capecitabine	Eisai	Phase 2	35
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Approved	43
Lenvatinib	Eisai	Pre-clinical	26
Bexarotene	Eisai	Phase 1	29
Lenvatinib + Lenvatinib matching placebo	Eisai	Phase 2	35
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
E7080 capsule	Eisai	Phase 2	35
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)	Eisai	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27